Adar1 Capital Management, LLC Protagonist Therapeutics, Inc Transaction History
Adar1 Capital Management, LLC
- $539 Billion
- Q1 2025
A detailed history of Adar1 Capital Management, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Adar1 Capital Management, LLC holds 939,669 shares of PTGX stock, worth $42.3 Million. This represents 8.44% of its overall portfolio holdings.
Number of Shares
939,669
Previous 1,020,333
7.91%
Holding current value
$42.3 Million
Previous $39.4 Billion
15.38%
% of portfolio
8.44%
Previous 7.87%
Shares
6 transactions
Others Institutions Holding PTGX
# of Institutions
299Shares Held
61.3MCall Options Held
1.01MPut Options Held
555K-
Farallon Capital Management LLC San Francisco, CA6.11MShares$275 Million1.7% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$259 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.72MShares$257 Million4.53% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.28MShares$193 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3MShares$135 Million5.07% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.21B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...